openPR Logo
Press release

Hiv Drugs Market Size 2020 | North America, Europe & Asia Pacific Regions to Dominate the Global Industry

01-15-2020 02:16 PM CET | Health & Medicine

Press release from: Fortune Business Insights Pvt. Ltd.

Hiv Drugs Market Size 2020 | North America, Europe & Asia Pacific

The global HIV/AIDS drugs market is likely to derive growth form the increasing prevalence of the disease across the world. According to a report published by Fortune Business Insights, titled “HIV/AIDS Drugs Market: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 25,314.0 Mn in 2018. Fortune Business Insights has predicted that the market will reach US$ 40,675.0 Mn by 2026, thereby exhibiting a CAGR of 6.1% in the forecast period

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/hiv-aids-drugs-market-101115

Leading Players operating in the Hiv Drugs Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

• ViiV Healthcare
• Gilead Sciences
• Merck Sharp & Dohme
• Bristol-Myers Squibb Company
• Janssen Pharmaceuticals
• Theratechnologies
• Mylan Pharmaceuticals
• Genentech
• AbbVie
Detailed Table of Content:

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Epidemiology of HIV/AIDS by Key Countries
4.2. Overview of Pipeline Analysis
4.3. Regulatory Scenario by Key Countries
4.4. Pricing Analysis
4.5. Key Strategies Employed by Market Leaders in Various Regions
4.6. Overview of New Product Launches
5. Global HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
5.2.2. Integrase Inhibitors
5.2.3. Combination HIV Medicines
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By Distribution Channel
5.3.1. Hospital Pharmacies
5.3.2. Retail Pharmacies
5.3.3. Online Pharmacies
5.3.4. Others
5.4. Market Analysis, Insights and Forecast – By Region
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Rest of World
6. North America HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis – By Drug Class
6.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
6.2.2. Integrase Inhibitors
6.2.3. Combination HIV Medicines
6.2.4. Others
6.3. Market Analysis – By Distribution Channel
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.3.4. Others
6.4. Market Analysis – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis – By Drug Class
7.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
7.2.2. Integrase Inhibitors
7.2.3. Combination HIV Medicines
7.2.4. Others
7.3. Market Analysis – By Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.3.4. Others
7.4. Market Analysis – By Country/ Sub-Region
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Italy
7.4.6. Scandinavia
7.4.7. Rest of Europe
8. Asia Pacific HIV-AIDS Drugs Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis – By Drug Class
8.2.1. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
8.2.2. Integrase Inhibitors
8.2.3. Combination HIV Medicines
8.2.4. Others
8.3. Market Analysis – By Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.3.4. Others
8.4. Market Analysis – By Country/ Sub-Region
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Southeast Asia
8.4.6. Rest of Asia Pacific
Continued...

Market Segmentation:

By Drug Class
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Integrase Inhibitors
• Combination HIV Medicines
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Geography
• North America (the USA and Canada)
• Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
• Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
• Rest of the World

Reasons to Purchase this Report:

• Comprehensive analysis of the Hiv Drugs Market growth drivers, obstacles, opportunities, and other related challenges.
• Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
• Identifies market restraints and boosters.
• Identifies all the possible segments present in the market to aid organizations in strategic business planning.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/hiv-aids-drugs-market-101115

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hiv Drugs Market Size 2020 | North America, Europe & Asia Pacific Regions to Dominate the Global Industry here

News-ID: 1897138 • Views:

More Releases from Fortune Business Insights Pvt. Ltd.

Luxury Goods Market Size Report, Trends, Overview, Outlook & Future Growth By 2030
Luxury Goods Market Size Report, Trends, Overview, Outlook & Future Growth By 20 …
The global luxury goods market size was valued at USD 272.74 billion in 2022. The market is anticipated to grow from USD 284.00 billion in 2023 to USD 392.40 billion by 2030, exhibiting a CAGR of 4.7% during the forecast period. Luxury products signify the status symbol of an individual. Businesses focus on high-income populations with visually appealing designs and technology-integrated products. For instance, NFC-installed chips in jewelry; a product called
With 17.2% CAGR, Smart Glass market Market to Hit USD 15,788.0 Million by 2022-2027 | Key Companies Profiled: BSG Glass, NSG Groupe, Schott AG
With 17.2% CAGR, Smart Glass market Market to Hit USD 15,788.0 Million by 2022-2 …
The global smart glass market size is anticipated to reach USD 15,788.0 million by 2027, owing to the rise in the use of smart glass for different applications such as aerospace, marine, architectural, and automotive. Smart glass or switchable glass is glazing or a glass with altered transmission properties as and when heat, light, or voltage is applied. They are capable of changing their appearance from opaque to translucent to transparent
Non-alcoholic Beverages Market Segmentation& Analysis, Industry Growth Forecast 2020-2027
Non-alcoholic Beverages Market Segmentation& Analysis, Industry Growth Forecast …
According to Fortune Business Insights ™, the global non-alcoholic beverages market size is anticipated to rise significantly on account of the current trend of health and fitness and the rising inclination towards healthy beverages. The value of this market was USD 919.13 billion in 2019 and is expected to rise at a CAGR of 8.20% between 2020 to 2027 to reach USD 1,257.77 billion by the end of 2027. List of
Intravenous Iron Drugs Market 2022: Global Technology, Segmentation, Growth, Development, Trends and Forecasts to 2027
Intravenous Iron Drugs Market 2022: Global Technology, Segmentation, Growth, Dev …
Global Intravenous Iron Drugs Market Size research report 2022 offers an in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market. The demand for refractive surgeries is anticipated to increase, attributed to the rise in the aging population and excessive use of digital devices, which has increased the screen time of the world population due to the

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug